Mohamed Saad, MD
Pulmonary Disease · Louisville, KYNPI 1275518516
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Pfizer at 54.7% of the total. Reporting peaked in 2023 at $8,766 and has fallen 98.9% since, to $92 in 2025.
Across 26 payments — averaging $618.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$9K
- Biohaven Pharmaceuticals, Inc.$7K
- Boehringer Ingelheim$275
- Pulmonx Corporation$163
- Inspire Medical Systems, Inc.$101
- Johnson & Johnson$76
- plus $168 from 4 others
Across 150 payments — averaging $2824.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$192K
- Roche Products Limited$93K
- Grifols Therapeutics LLC$48K
- Cumberland Pharmaceuticals, Inc.$45K
- Jazz Pharmaceuticals Inc.$36K
- La Jolla Pharmaceutical Company$10K
What the payments were for
- Consulting fees$6,50040%
- Speaking & faculty fees$8,75054%
- Food & beverage$8275%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $8,794 |
| Biohaven Pharmaceuticals, Inc. | 1 | $6,500 |
| Boehringer Ingelheim | 5 | $275 |
| Pulmonx Corporation | 2 | $163 |
| Inspire Medical Systems, Inc. | 1 | $101 |
| Johnson & Johnson(2 entities) | 2 | $76 |
| Genentech USA, Inc. | 4 | $73 |
| Electromed, Inc. | 4 | $48 |
| Actelion Pharmaceuticals US, Inc. | 1 | $31 |
| Sanofi | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,077 in reported general payments places this provider in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $93,695 |
| Dupixent PenDupilumab | 25 | $93,260 |
| Breo ElliptaFluticasone/Vilanterol | 83 | $43,281 |
| Spiriva HandihalerTiotropium Bromide | 25 | $19,755 |
| Spiriva RespimatTiotropium Bromide | 27 | $18,813 |
| NeuproRotigotine | 13 | $17,058 |
| SymbicortBudesonide/Formoterol Fumarate | 56 | $13,942 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $13,787 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $13,171 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $12,156 |
| BelsomraSuvorexant | 24 | $11,087 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,890 |
| Tiotropium Bromide | 14 | $6,992 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,532 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 145 | $3,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $275 | $31,98439 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- John McConnellLouisville$864K
- Harold HallerLouisville$340K
- Samantha BaahLouisville$226K
- Karim El-KershLouisville$180K
- Josephine MeiLouisville$101K
- Maroun GhosseinLouisville$34K
- Moutaz Al NabhanLouisville$24K
- Sally SulimanLouisville$21K
- Mark EsterleLouisville$19K
- Kenneth AndersonLouisville$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.